EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

When Hepatitis Masks Visceral Leishmaniasis: A Case of Secondary HLH in a Low‐Endemic Region

Chernet T Mengistie iD, Biruk T Mengistie iD, Temesgen H Gebremeskel iD, Thomas M Muluneh, Rediet G Kebede

Clinical Case Reports · 2025-10 · 13 (10)

DOI: 10.1002/ccr3.71351 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Case Reports, online erschienen am 23.10.2025. Verfasst von Chernet T Mengistie und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Health Sciences Addis Ababa University Addis Ababa Ethiopia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Visceral leishmaniasis (VL)–associated hemophagocytic lymphohistiocytosis (HLH) is a rare but life‐threatening hyperinflammatory syndrome. Diagnosis is often challenging due to overlapping clinical features, especially in low‐endemic regions, where VL is not initially suspected. Severe hepatic dysfunction can further obscure the diagnosis and complicate treatment. We report a 14‐year‐old male from West Gojjam, Ethiopia, presenting initially with jaundice and clinical features of acute hepatitis. Over 3 months, he developed progressive abdominal distension, fever, pancytopenia, and coagulopathy. Imaging showed hepatosplenomegaly and ascites; viral and autoimmune hepatitis were excluded. Bone marrow examination revealed Leishmania donovani amastigotes and hemophagocytosis, confirming VL‐triggered secondary HLH. Due to severe hepatic impairment, etoposide was withheld. The patient was treated with intravenous dexamethasone and a six‐day course of liposomal amphotericin B, along with supportive care. Clinical and laboratory parameters improved steadily, with full recovery by 4 weeks. VL‐HLH should be considered in patients with hepatitis‐like presentations, even in low‐endemic areas. Early recognition and treatment targeting the underlying infection with amphotericin B plus corticosteroids can achieve favorable outcomes, even when etoposide is contraindicated.

Schlagwörter

Stichwörter der Autor:innen

hemophagocytic lymphohistiocytosishepatitis‐like presentationliposomal amphotericin Bsecondary HLHvisceral leishmaniasis

Autor:innen und Institutionen

  • School of Medicine, College of Health Sciences Addis Ababa University Addis Ababa Ethiopia.

ORCID-Profile: Chernet T Mengistie, Biruk T Mengistie, Temesgen H Gebremeskel

Zitieren

APA

Mengistie, C. T., Mengistie, B. T., Gebremeskel, T. H., Muluneh, T. M., & Kebede, R. G. (2025). When Hepatitis Masks Visceral Leishmaniasis: A Case of Secondary HLH in a Low‐Endemic Region. Clinical Case Reports, 13(10). https://doi.org/10.1002/ccr3.71351

Vancouver

Mengistie CT, Mengistie BT, Gebremeskel TH, Muluneh TM, Kebede RG. When Hepatitis Masks Visceral Leishmaniasis: A Case of Secondary HLH in a Low‐Endemic Region. Clinical Case Reports. 2025;13(10). doi:10.1002/ccr3.71351

BibTeX
@article{Mengistie2025,
  author = {Mengistie, Chernet T and Mengistie, Biruk T and Gebremeskel, Temesgen H and Muluneh, Thomas M and Kebede, Rediet G},
  title = {When Hepatitis Masks Visceral Leishmaniasis: A Case of Secondary HLH in a Low‐Endemic Region},
  journal = {Clinical Case Reports},
  year = {2025},
  volume = {13},
  number = {10},
  doi = {10.1002/ccr3.71351}
}
Kostenlos starten →